• Epirubicin is an anthracycline drug used for chemotherapy. (wikipedia.org)
  • Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some chemotherapy regimens as it appears to cause fewer side-effects. (wikipedia.org)
  • Epirubicin monotherapy was shown to be therapeutically equivalent to doxorubicin monotherapy in patients who had to receive previous chemotherapy for advanced breast cancer. (wikipedia.org)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. (ersjournals.com)
  • The first-line treatment of ES-SCLC currently consists of chemotherapy with a platinum derivative and etoposide, a combination that was first reported to be effective in the treatment of SCLC in 1985 8 , 9 . (ersjournals.com)
  • Chemotherapy may be given with a curative intent (which almost always involves combinations of drugs) or it may aim to prolong life or to reduce symptoms (palliative chemotherapy). (worldsbest.rehab)
  • continued to use CP either alone or in combination with other agents in cancer chemotherapy due to its efficacy. (researchwap.com)
  • It can be used alone, or together with certain other medicines as part of combination chemotherapy. (trionepharma.com)
  • METHODS: This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer. (bvsalud.org)
  • Equimolar doses of epirubicin and doxorubicin have been shown to be therapeutically equivalent in patients with metastatic breast cancer. (wikipedia.org)
  • Additionally the administration of more dose intensive epirubicin-containing regimens to patients with metastatic breast cancer has been associated with improved response rates, but not increased overall survival. (wikipedia.org)
  • Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis, had been approved for use in combination therapy for metastatic breast cancer. (medscape.com)
  • Palbociclib and ribociclib are cyclin-dependent kinases (CDK) 4, 6 inhibitors indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (medscape.com)
  • We applied four, five or six cycles of moderately high doses of doxorubicin and cyclophosphamide supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). (coek.info)
  • In a retrospective survey, including 9144 patients, mostly with solid tumors in advanced stages, the probability of developing CHF increased with increasing cumulative doses of Epirubicin Hydrochloride Injection (Figure 5). (recallguide.org)
  • The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. (medilib.ir)
  • Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. (trillium.de)
  • Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E, "Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix," Eur J Gynaecol Oncol, 24(3-4):323-6 (2003). (yesimeralp.com)
  • 40 mg/m 2 on day 1 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) (Fassnacht 2012) or 20 mg/m 2 on days 1 and 8 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (Berruti 2005). (medilib.ir)
  • Sternberg 2006) or 30 mg/m 2 on day 1 every 28 days (in combination with methotrexate, vinblastine, cisplatin, and filgrastim) for up to 6 cycles or until loss of clinical benefit (Bamias 2004). (medilib.ir)
  • Our Herzuma (trastuzumab-pkrb) for Injection, for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • HERZUMA (trastuzumab-pkrb) is a sterile, white to pale yellow, preservative-free lyophilized powder for injection, for intravenous administration. (rxlist.com)
  • Epirubicin Hydrochloride Injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. (recallguide.org)
  • Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with Epirubicin Hydrochloride Injection. (recallguide.org)
  • This toxicity appears to be dependent on the cumulative dose of Epirubicin Hydrochloride Injection and represents the cumulative dose-limiting toxicity of the drug. (recallguide.org)
  • If it occurs, delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin Hydrochloride Injection or within 2 to 3 months after completion of treatment, but later events (several months to years after treatment termination) have been reported. (recallguide.org)
  • It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. (wikipedia.org)
  • As pegylated liposomal formulation: In combination with bortezomib for the treatment of progressive cases in patients who have undergone or are unsuitable for a bone marrow transplant and who have received at least 1 prior therapy: 30 mg/m 2 on day 4 of the bortezomib 3 week regimen given via infusion over 60 minutes immediately after bortezomib infusion. (azurewebsites.net)
  • Page 1 INTRAVENOUS CANCER TREATMENT EDUCATION NIVOLUMAB Name of the regimen and cancer drugs Nivolumab (nih VOL yoo mab): Opdivo Common uses Nivolumab is used to treat many different types of cancer, including melanoma, classical Hodgkin Lymphoma, and lung, head and neck, esophageal, bladder, colorectal, liver, and kidney cancers. (ivcanceredsheets.com)
  • BT-ON014 trade name] intravenous formulation is not intended for subcutaneous administration and should be administered via an intravenous infusion only. (who.int)
  • IV (intravenous) infusion. (aultcare.com)
  • Epirubicin is also capable of generating cytotoxic free radicals, which are very reactive against DNA, cell membranes and mitochondria. (wikipedia.org)
  • Rats in group (8) received combination of V. amygdalina and O. gratissimum at a dose of 250 mg/kg each for ten consecutive before administering CP (200 mg/kg) on the tenth day. (researchwap.com)
  • Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer and lymphomas. (wikipedia.org)
  • Epirubicin has a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar - it has the opposite chirality - which may account for its faster elimination and reduced toxicity. (wikipedia.org)
  • Early cardiac toxicity of epirubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes, but tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. (recallguide.org)
  • Epirubicin is a stereoisomer of doxorubicin with the same indications as but slightly lesser potency and less cardiac toxicity than the parent drug. (allindianpatents.com)
  • Epirubicin then stabilizes the topoisomerase II-DNA complex, resulting in irreversible DNA strand breakage, leading to cell death. (wikipedia.org)
  • Treatment schedule Your treatment will be given into your vein through an intravenous (IV) line. (ivcanceredsheets.com)
  • The median survival rates markedly better than those achieved with epirubicin monotherapy. (wikipedia.org)
  • 139] Since these data were published, a subsequent analysis with an additional 11 months of follow-up showed that the median PFS was 25.3 months with the ribociclib combination vs 16 months with letrozole alone, according to a company statement. (medscape.com)
  • Monitoring for potential cardiotoxicity is also important, especially with greater cumulative exposure to epirubicin. (recallguide.org)
  • As conventional formulation: As a component of adjuvant therapy (multi-agent) in women with axillary lymph node involvement following resection of primary breast cancer: In combination with cyclophosphamide: 60 mg/m 2 on day 1 of each 21-day treatment cycle, for a total of 4 cycles. (azurewebsites.net)
  • Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, "Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group," Cancer Investigation 21(5),737-43 (2003). (yesimeralp.com)
  • These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not considered an indication for the suspension of epirubicin treatment. (recallguide.org)
  • 14 Cycle 2 Day 1 Nivolumab X X NIVOLUMAB Page 2 INTRAVENOUS CANCER TREATMENT EDUCATION Common Side Effects Common side effects that have been known to happen in patients receiving nivolumab are listed in the left side of this table. (ivcanceredsheets.com)
  • Investigate optimal type, duration, and sequence/combination of treatment interventions for HCC used in usual clinical practice 2. (rwjbh.org)
  • Assess left ventricular ejection fraction before and regularly during and after treatment with doxorubicin. (medilib.ir)
  • It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. (wikipedia.org)
  • If myelosuppressive complications occur, appropriate supportive measures (e.g., intravenous antibiotics, colony-stimulating factors, transfusions) may be required. (recallguide.org)
  • The combination of Epirubicin and tamoxifen lead to an increase survival in node-positive postmenopausal women with hormone receptor-positive breast tumours. (wikipedia.org)
  • Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. (medilib.ir)
  • Epirubicin exhibits activity in all phases of the cell cycle, but maximal cell kill occurs during the S and G2 phases of the cell cycle. (wikipedia.org)
  • When using nivolumab plus cabozantinib combination therapy for a tumor with bronchial invasion, physicians should be aware of bronchial perforation as the tumor shrinks. (bvsalud.org)
  • The aim of Epirubicin as adjuvanted therapy is to eradicate micro metastasis and prolong disease free survival. (wikipedia.org)
  • The approval of palbociclib for ER+/HER2- advanced breast cancer in combination with fulvestrant in women (regardless of menopausal status) with disease progression following endocrine therapy was based on the PALOMA-3 trial (n=521). (medscape.com)
  • In combination with other antineoplastic agents: 30-60 mg/m 2 every 3 weeks, or 40-75 mg/m 2 every 21-28 days. (azurewebsites.net)
  • Using a combination increases the chance of killing a larger number of cells. (owise.uk)
  • Doctors prescribe epirubicin alongside other medications to treat breast cancer in people who have already had surgery to remove the tumor. (medicalnewstoday.com)
  • However, there are some combinations that can be used to treat advanced breast cancer. (owise.uk)
  • The observed clinical differences between epirubicin and doxorubicin can be explained by the pharmacokinetic differences based on the different affinity to DNA and lipophilicity, as there is no indication that different mechanisms are involved in their activity. (wikipedia.org)
  • Epirubicin also generates free radicals that cause cell and DNA damage. (wikipedia.org)
  • The LNA oligonucleotides are superior to other LNA oligonucleotides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides. (justia.com)